What was the median recurrence-free survival (rfs) in RELATIVITY-098?

Reconstructed medians (Months): NIVO + RELA not reached; NIVO 32.9. See the published article for the official values.

What was the hazard ratio for recurrence-free survival (rfs) in RELATIVITY-098?

The figure reports a hazard ratio of 1.01 (95% CI 0.83–1.22). TrialCurve's reconstruction gives 1.01.

What was the median distant metastasis-free survival (dmfs) in RELATIVITY-098?

Reconstructed medians (Months): NIVO + RELA not reached; NIVO not reached. See the published article for the official values.

What was the hazard ratio for distant metastasis-free survival (dmfs) in RELATIVITY-098?

The figure reports a hazard ratio of 1.07 (95% CI 0.84–1.36). TrialCurve's reconstruction gives 1.03.

What was the median overall survival in RELATIVITY-098?

Reconstructed medians (Months): NIVO + RELA not reached; NIVO not reached. See the published article for the official values.

What was the hazard ratio for overall survival in RELATIVITY-098?

The figure reports a hazard ratio of 1.24 (95% CI 0.9–1.72). TrialCurve's reconstruction gives 1.23.

Home / Trials

RELATIVITY-098: reconstructed Kaplan–Meier curves

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

Publication	Nat Med. 2025 Oct 18;31(12):4301–9. doi: 10.1038/s41591-025-04032-8
DOI	10.1038/s41591-025-04032-8
Registry	NCT05002569
Phase	Phase 3
Conditions	Melanoma
Interventions	Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Sponsor	Bristol-Myers Squibb
Enrolment	1093
Source licence	Figure published under CC BY 4.0

Recurrence-free survival (RFS) — All randomized patients

From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: NIVO + RELA not reached; NIVO 32.9 months. Survival at 12 months: NIVO + RELA 74%; NIVO 71%. Hazard ratio NIVO + RELA vs NIVO 0.99 (95% CI 0.82–1.19).

Arm	N	Events	Median (Months)
NIVO + RELA	547	218	not reached
NIVO	546	221	32.9

NIVO + RELA vs NIVO: reconstructed HR 0.99 (95% CI 0.82–1.19)

Landmark survival (reconstructed)

Time	NIVO + RELA	NIVO
6 mo	82.6%	79.8%
12 mo	74.1%	71.0%
18 mo	68.4%	66.4%
24 mo	61.5%	61.7%
36 mo	53.4%	—

Checks against the published figure

NIVO median: printed 33.1, reconstructed 32.9 pass
NIVO + RELA events: printed 214, reconstructed 218 pass
NIVO + RELA n: printed 547, reconstructed 547 pass
NIVO events: printed 213, reconstructed 221 pass
NIVO n: printed 546, reconstructed 546 pass
hazard ratio (direction inferred): printed 1.01, reconstructed 1.01 pass

Download pseudo-IPD (CSV)

Distant metastasis-free survival (DMFS) — Subset of intention-to-treat patients with resected stage III-IVA-IVB melanoma

From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: NIVO + RELA not reached; NIVO not reached. Survival at 12 months: NIVO + RELA 85%; NIVO 83%. Hazard ratio NIVO vs NIVO + RELA 0.97 (95% CI 0.76–1.23).

Arm	N	Events	Median (Months)
NIVO + RELA	499	134	not reached
NIVO	494	132	not reached

NIVO vs NIVO + RELA: reconstructed HR 0.97 (95% CI 0.76–1.23)

Landmark survival (reconstructed)

Time	NIVO + RELA	NIVO
6 mo	90.0%	88.9%
12 mo	84.6%	83.4%
18 mo	79.0%	80.2%
24 mo	72.5%	76.3%

Checks against the published figure

NIVO + RELA events: printed 133, reconstructed 134 pass
NIVO + RELA n: printed 499, reconstructed 499 pass
NIVO events: printed 129, reconstructed 132 pass
NIVO n: printed 494, reconstructed 494 pass
hazard ratio (direction inferred): printed 1.07, reconstructed 1.03 pass

Download pseudo-IPD (CSV)

Overall survival

From figure panel · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: NIVO + RELA not reached; NIVO not reached. Survival at 12 months: NIVO + RELA 96%; NIVO 96%. Hazard ratio NIVO vs NIVO + RELA 0.81 (95% CI 0.58–1.12).

Arm	N	Events	Median (Months)
NIVO + RELA	547	80	not reached
NIVO	546	65	not reached

NIVO vs NIVO + RELA: reconstructed HR 0.81 (95% CI 0.58–1.12)

Landmark survival (reconstructed)

Time	NIVO + RELA	NIVO
6 mo	99.4%	99.3%
12 mo	95.7%	95.9%
18 mo	92.4%	92.8%
24 mo	88.6%	90.1%
36 mo	83.1%	86.8%

Checks against the published figure

NIVO + RELA events: printed 81, reconstructed 80 pass
NIVO + RELA n: printed 547, reconstructed 547 pass
NIVO events: printed 67, reconstructed 65 pass
NIVO n: printed 546, reconstructed 546 pass
hazard ratio (direction inferred): printed 1.24, reconstructed 1.23 pass

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Related trials

SCANDIUM: Hepatic progression-free survival (blinded central review); Progression-free survival (bli
MIND-DC: Overall survival; Recurrence-free survival

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials